An observational study in Viral Pulmonary Infections, sponsored by Gérond'if. Recruiting at 20 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Gérond'if · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Severe acute respiratory infections (SARIs) represent one of the leading causes of hospitalization and mortality worldwide. These infections are associated with substantial in-hospital mortality and often constitute a turning point in the medium-term prognosis of older patients and those with comorbid conditions.
SARIs are most frequently of viral origin, involving well-known pathogens such as Orthomyxoviridae (influenza A and B viruses), Pneumoviridae [(respiratory syncytial virus (RSV), human metapneumovirus (hMPV)], Paramyxoviridae [parainfluenza viruses (PIV)], adenoviruses, or rhinoviruses, as well as emerging viruses such as pandemic influenza strains and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic.
Age-related immune decline (immunosenescence) increases the risk of severe forms and related respiratory or cardiovascular complications. However, the prevalence and burden of the different viral etiologies of Severe acute respiratory infections (SARIs) in older adults remain limited and insufficiently characterized.
The primary objective is to determine the proportion of viral respiratory infections attributable to polymerase chain reaction (PCR)-confirmed pathogen agents among hospitalized older subjects (≥60 years old).
This is an observational, prospective, multicentre study in hospitalized older patients (≥60 years old) who have undergone viral respiratory sampling (RT-PCR or multiplex RT-PCR).
Subjects will be recruited over a period of 24 months at approximately 20 centres. Each subject will participate in the study for 3 months (Screening/inclusion visit and 3-month follow-up phone calls post hospital discharge). A respiratory sample (nasopharyngeal or nasal swab, oropharyngeal swab, aspirate, or bronchoalveolar lavage fluid) will be collected as part of standard of care and analysed by the local virology laboratory for the detection of respiratory virus(es) responsible for the infection, using validated Reverse transcription polymerase chain reaction (RT-PCR) or multiplex RT-PCR assays.
Gérond'if is the lead sponsor of 35 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospitalized older patients (≥60 years old) tested for PCR as part of standard of care (SoC). Subjects meeting the eligibility criteria will be invited to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Reasons for PCR:
Systematic PCR testing (in the context of clusters or during the winter season) * Recent onset of at least one general symptom and at least one functional or physical respiratory sign
Exclusion Criteria:
Subjects admitted to palliative care unit.
Number of RT-PCR-confirmed positive cases for viral pathogen agents of interest among hospitalized older subjects (≥60 years old)
Time frame: At baseline
Number of RT-PCR-confirmed positive cases for each viral pathogen agent of interest among hospitalized older subjects
Time frame: From baseline to 3-month follow-up
Number of RT-PCR-confirmed positive cases for each viral pathogen of interest among hospitalized older subjects according to the vaccination status
Time frame: From baseline to 3-month follow-up
Number of RT-PCR -confirmed positive cases for each viral respiratory pathogen of interest among hospitalized older subjects according to the indication of PCR
Time frame: From baseline to 3-month follow-up
Comparison of the prevalence of viral respiratory pathogen of interest among hospitalized older subjects by age groups
Time frame: From baseline to 3-month follow-up
Hospital burden of acute respiratory infections
including: * Mortality (in-hospital and at 3-month follow-up) * Length of hospital stay, admissions to intensive or critical care units, and use of ventilatory support (mechanical ventilation) * In-hospital geriatric syndromes: • Delirium: CAM (Confusion Assessment Method) score • Malnutrition: weight loss, serum albumin • Sarcopenia: one-leg stance test (unipedal stance test), Timed Up and Go (TUG) test (at admission and discharge) • Cognitive impairment: MMSE (Mini-Mental State Examination) score • Pressure ulcers * Extra-respiratory complications (in-hospital and during follow-up): • Cardiovascular complications (acute coronary syndrome, heart failure, atrial fibrillation, stroke) • Non-cardiovascular complications (digestive disorders, non-respiratory infections, acute kidney injury, metabolic disorders, etc.) * Functional autonomy: 15 days before hospitalization, at discharge, and at 3 months using ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) sc
Time frame: From baseline to 3 month follow up
Hospital burden of acute viral respiratory infections according to the indication of PCR
Time frame: From baseline to 3 month follow up
Prevalence of co-infections with the viral respiratory pathogens of interest among hospitalized older subjects.
Time frame: From baseline to 3-month follow-up
Patient characterization by age, sex, associated protective and risk factors, overall and by viral pathogen.
Time frame: At baseline
Epidemiological trends and seasonality of respiratory viruses during the study period.
Time frame: From baseline to 3 month follow up
Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 26 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jun 2026 → Oct 2026, primary completion Sep 2028 → Jan 2029 and completion Sep 2028 → Jan 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gérond'if